Literature DB >> 15069464

Should cognitive deficit be a diagnostic criterion for schizophrenia?

Ralph Lewis1.   

Abstract

This review examines the question of whether cognitive deficits in schizophrenia are sufficiently reliable, stable and specific to warrant inclusion in the diagnostic criteria for schizophrenia. The literature provides evidence that cognitive deficits are highly prevalent and fairly marked in adult patients with schizophrenia. Similar deficits have been found in children and adolescents with schizophrenia, and in children before they exhibit the signs and symptoms of schizophrenia. These deficits may in fact be central to the pathophysiology underlying the development of overt psychosis in schizophrenia. The deficits appear to be relatively stable across the course of the illness. They are generally more severe in schizophrenia than in affective disorders and may have a relatively specific pattern in schizophrenia. It is concluded that the evidence that cognitive deficits are a core feature of schizophrenia is sufficiently compelling to warrant inclusion of these deficits in the diagnostic criteria for schizophrenia, at least as a nonessential criterion.

Entities:  

Mesh:

Year:  2004        PMID: 15069464      PMCID: PMC383342     

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN: 1180-4882            Impact factor:   6.186


  107 in total

Review 1.  Measuring neuropsychological change in schizophrenia with novel antipsychotic medications.

Authors:  S E Purdon
Journal:  J Psychiatry Neurosci       Date:  2000-03       Impact factor: 6.186

Review 2.  Course of schizophrenia: neuropsychological evidence for a static encephalopathy.

Authors:  T E Goldberg; T M Hyde; J E Kleinman; D R Weinberger
Journal:  Schizophr Bull       Date:  1993       Impact factor: 9.306

3.  Neuropsychological deficits in pediatric patients with childhood-onset schizophrenia and psychotic disorder not otherwise specified.

Authors:  S Kumra; E Wiggs; J Bedwell; A K Smith; E Arling; K Albus; S D Hamburger; K McKenna; L K Jacobsen; J L Rapoport; R F Asarnow
Journal:  Schizophr Res       Date:  2000-04-07       Impact factor: 4.939

4.  Memory functioning in chronic and non-chronic schizophrenics, affectively disturbed patients and normal controls.

Authors:  N I Landrø; A L Orbeck; B R Rund
Journal:  Schizophr Res       Date:  1993-06       Impact factor: 4.939

5.  Cognitive functions and psychopathological symptoms in early-onset schizophrenia.

Authors:  T Banaschewski; E Schulz; M Martin; H Remschmidt
Journal:  Eur Child Adolesc Psychiatry       Date:  2000-03       Impact factor: 4.785

6.  Childhood cognitive functioning in schizophrenia patients and their unaffected siblings: a prospective cohort study.

Authors:  T D Cannon; C E Bearden; J M Hollister; I M Rosso; L E Sanchez; T Hadley
Journal:  Schizophr Bull       Date:  2000       Impact factor: 9.306

Review 7.  Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?

Authors:  M F Green; R S Kern; D L Braff; J Mintz
Journal:  Schizophr Bull       Date:  2000       Impact factor: 9.306

8.  Neuropsychological deficits in schizophrenics. Relationship to age, chronicity, and dementia.

Authors:  R Heaton; J S Paulsen; L A McAdams; J Kuck; S Zisook; D Braff; J Harris; D V Jeste
Journal:  Arch Gen Psychiatry       Date:  1994-06

Review 9.  Impaired attention, genetics, and the pathophysiology of schizophrenia.

Authors:  B A Cornblatt; J G Keilp
Journal:  Schizophr Bull       Date:  1994       Impact factor: 9.306

10.  Backward masking in schizophrenia and mania. I. Specifying a mechanism.

Authors:  M F Green; K H Nuechterlein; J Mintz
Journal:  Arch Gen Psychiatry       Date:  1994-12
View more
  26 in total

Review 1.  Is there evidence for late cognitive decline in chronic schizophrenia?

Authors:  Jharna N Shah; Salah U Qureshi; Ali Jawaid; Paul E Schulz
Journal:  Psychiatr Q       Date:  2012-06

2.  SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist, alleviates disturbances of novelty discrimination in a social context in rats, a putative model of selective attention deficit.

Authors:  J-P Terranova; C Chabot; M-C Barnouin; G Perrault; R Depoortere; G Griebel; B Scatton
Journal:  Psychopharmacology (Berl)       Date:  2005-04-14       Impact factor: 4.530

Review 3.  Schizophrenia: an integrative approach to modelling a complex disorder.

Authors:  George S Robertson; Sarah E Hori; Kelly J Powell
Journal:  J Psychiatry Neurosci       Date:  2006-05       Impact factor: 6.186

Review 4.  Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties.

Authors:  Adrian Newman-Tancredi; Mark S Kleven
Journal:  Psychopharmacology (Berl)       Date:  2011-03-11       Impact factor: 4.530

5.  Associations of SNAP-25 polymorphisms with cognitive dysfunctions in Caucasian patients with schizophrenia during a brief trail of treatment with atypical antipsychotics.

Authors:  Ilja Spellmann; Norbert Müller; Richard Musil; Peter Zill; Anette Douhet; Sandra Dehning; Anja Cerovecki; Brigitta Bondy; Hans-Jürgen Möller; Michael Riedel
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-03-17       Impact factor: 5.270

Review 6.  Effect of N-acetyl cysteine (NAC) supplementation on positive and negative syndrome scale in schizophrenia: a systematic review and meta-analysis of randomised controlled trials.

Authors:  Amir Ghaderi; Anna Bussu; Catherine Tsang; Sadegh Jafarnejad
Journal:  Eur J Clin Pharmacol       Date:  2018-11-16       Impact factor: 2.953

7.  Risperidone and ritanserin but not haloperidol block effect of dizocilpine on the active allothetic place avoidance task.

Authors:  Vera Bubenikova-Valesova; Ales Stuchlik; Jan Svoboda; Jan Bures; Karel Vales
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-14       Impact factor: 11.205

8.  Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia.

Authors:  Michael Riedel; Norbert Müller; Ilja Spellmann; Rolf R Engel; Richard Musil; Rosamaria Valdevit; Sandra Dehning; Anette Douhet; Anja Cerovecki; Martin Strassnig; Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2007-10       Impact factor: 5.270

9.  Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms.

Authors:  Michael Riedel; Ilja Spellmann; Martin Strassnig; Anette Douhet; Sandra Dehning; Markus Opgen-Rhein; Rosamaria Valdevit; Rolf R Engel; Nikolaus Kleindienst; Norbert Müller; Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2007-07-14       Impact factor: 5.270

Review 10.  Myelin, copper, and the cuprizone model of schizophrenia.

Authors:  Nicole R Herring; Christine Konradi
Journal:  Front Biosci (Schol Ed)       Date:  2011-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.